Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion.

IF 2.4 3区医学 Q2 OPHTHALMOLOGY

Graefe’s Archive for Clinical and Experimental Ophthalmology Pub Date : 2024-12-01 Epub Date: 2024-07-22 DOI:10.1007/s00417-024-06562-2

Erdem Dursun, Baki Derhem, Seval Çobanoğlu, Tevfik Oğurel

{"title":"Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion.","authors":"Erdem Dursun, Baki Derhem, Seval Çobanoğlu, Tevfik Oğurel","doi":"10.1007/s00417-024-06562-2","DOIUrl":null,"url":null,"abstract":"Background: We aimed to investigate the effect of retinal vein occlusion (RVO) on the posterior segment structures of the eye and its changes with intravitreal anti-Vascular Endothelial Growth Factor (VEGF) treatment.Methods: This prospective longitudinal study included 29 eyes of 29 patients with RVO (17 males and 12 females) followed for 6 months. The best corrected visual acuity (BCVA), macula, choroid ticknesses and choroidal vascularity index (CVI) obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the first injection. Results were compared with fellow eyes (non-affected eyes) and age- and sex-matched controls.Results: BCVA increased significantly in the 6th month, more in the first month of injection (p < 0.05 for each). Central macular tickness, subfoveal choroid tickness, stromal and total area of choroid decreased significantly after injection (p < 0.05 for each). CVI values increased significantly, especially in the 1st month after injection (p < 0.05 for each). In eyes with Branch RVO, there was a significant decrease in the macular thickness of the occlusive areas with treatment, while there was no statistically significant change in the non-occlusive macular thickness.Conclusion: Observation of changes in choroidal structure may be useful to assess the activity of RVO and predict the efficacy of anti-VEGF therapy.","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"3837-3845"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608387/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Graefe’s Archive for Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00417-024-06562-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We aimed to investigate the effect of retinal vein occlusion (RVO) on the posterior segment structures of the eye and its changes with intravitreal anti-Vascular Endothelial Growth Factor (VEGF) treatment.

Methods: This prospective longitudinal study included 29 eyes of 29 patients with RVO (17 males and 12 females) followed for 6 months. The best corrected visual acuity (BCVA), macula, choroid ticknesses and choroidal vascularity index (CVI) obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the first injection. Results were compared with fellow eyes (non-affected eyes) and age- and sex-matched controls.

Results: BCVA increased significantly in the 6th month, more in the first month of injection (p < 0.05 for each). Central macular tickness, subfoveal choroid tickness, stromal and total area of choroid decreased significantly after injection (p < 0.05 for each). CVI values increased significantly, especially in the 1st month after injection (p < 0.05 for each). In eyes with Branch RVO, there was a significant decrease in the macular thickness of the occlusive areas with treatment, while there was no statistically significant change in the non-occlusive macular thickness.

Conclusion: Observation of changes in choroidal structure may be useful to assess the activity of RVO and predict the efficacy of anti-VEGF therapy.

Abstract Image

查看原文本刊更多论文

研究视网膜静脉阻塞患者接受玻璃体内抗血管内皮生长因子治疗后脉络膜结构的变化。

背景：我们的目的是研究视网膜静脉阻塞（RVO）对眼球后段结构的影响及其在玻璃体内抗血管内皮生长因子（VEGF）治疗后的变化：这项前瞻性纵向研究纳入了 29 名 RVO 患者（男 17 名，女 12 名）的 29 只眼睛，随访 6 个月。在基线和首次注射后的第一、第三和第六个月，记录通过光谱域光学相干断层扫描获得的最佳矫正视力（BCVA）、黄斑、脉络膜厚度和脉络膜血管指数（CVI）。结果与同侧眼睛（未受影响的眼睛）以及年龄和性别匹配的对照组进行了比较：结果：BCVA在第6个月明显增加，注射后第1个月增加较多（P观察脉络膜结构的变化可能有助于评估 RVO 的活动性和预测抗 VEGF 治疗的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Graefe’s Archive for Clinical and Experimental Ophthalmology 医学-眼科学

CiteScore

5.40

自引率

7.40%

发文量

398

审稿时长

3 months

期刊介绍： Graefe''s Archive for Clinical and Experimental Ophthalmology is a distinguished international journal that presents original clinical reports and clini-cally relevant experimental studies. Founded in 1854 by Albrecht von Graefe to serve as a source of useful clinical information and a stimulus for discussion, the journal has published articles by leading ophthalmologists and vision research scientists for more than a century. With peer review by an international Editorial Board and prompt English-language publication, Graefe''s Archive provides rapid dissemination of clinical and clinically related experimental information.